Navigation Links
Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
Date:12/8/2012

COLUMBUS, Ohio Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy.

The agent, ibrutinib (PCI-32765), is the first drug designed to target Bruton's tyrosine kinase (BTK), a protein essential for CLL-cell survival and proliferation. CLL is the most common form of leukemia, with about 15,000 new cases annually in the U.S. About 4,400 Americans die of the disease each year.

Study co-leader Dr. John C. Byrd, director of the division of hematology at Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) presented these findings today (12/8) at the 54th Annual Meeting of the American Society of Hematology (ASH) Annual Meeting in Atlanta, GA.

The study found that response to therapy was high across cohorts, with 71 percent of previously untreated older patients experiencing a complete or partial response at either treatment dose (420mg and 840mg). The same response was observed in 67 percent of the relapsed patients and half (50%) of the high-risk patient cohort. After 22 months of follow-up, the disease had not progressed in 96 percent of previously untreated patients and 76 percent of relapsed and high-risk patients.

"These findings are truly exciting because they demonstrate ibrutinib's potential as a highly active, well-tolerated first-line therapy for CLL that produces a high rate of durable remissions the remissions last months on end," Byrd says. "The drug is effective in part because patients are willing to stay on treatment since the side effects are very tolerable," he states.

Only non-severe side effects, including diarrhea, fatigue, chest infection, rash, nausea, joint pain and infrequent and transient low blood counts were observed. Investigators found no evidence of c
'/>"/>

Contact: Liz Bryan, Spectrum
lbryan@spectrumscience.com
443-506-1931
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. EzCheckPrinting Updated with New Category Feature to Simplify Check Printing and Tax Reporting
2. Winning the battle against leukaemia: Positive early results in clinical trial for DNA vaccine
3. Pure Cocoa Powder, the Key Ingredient in Dark Chocolate and Found in Diabetes Support Supplements has been Clinically Proven to Reduce Cardiovascular Risk
4. USC Norris cancer research ranks among top clinical advances for 2012
5. American Society of Clinical Oncology issues annual report on state of clinical cancer science
6. Clinical trial at GHSU Cancer Center targets advanced prostate cancer
7. Study finds link between access to online health information and use of clinical services
8. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
9. Molecular portraits of tumours match patients with trials in everyday clinical practice
10. New targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials
11. Spread of human melanoma cells in mice correlates with clinical outcomes in patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... Dr. Paul Kovatis of Orthopedic Spine ... At OSSMC, Dr. Kovatis treats all surgical and non-surgical disorders of the leg, ankle ... entire musculoskeletal system, excluding the spine. , Dr. Paul Kovatis completed his orthopedic leg, ...
(Date:8/31/2015)... ... August 31, 2015 , ... How can healthcare ... hold down costs? , In a commentary for The American Journal of ... concept of “clinical efficacy,” which would bind parties together in agreements to intervene ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... at the 16th Innovations in Healthcare(SM) Awards Event , on October 21, ... (ABL) Organization , recognizes innovative organizations and individuals who are dramatically reducing the ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dad Phil, ... ribbon-cutting ceremony on Aug. 26, generously hosted by the Collinsville Chamber of Commerce, ... AdvantaClean’s National Call Center and website since Aug. 17. , The Greens have ...
(Date:8/31/2015)... ... August 31, 2015 , ... DR. LUCIANA ON ... (aka Dr. Luciana) received a total of three Silver Medal awards at ... Best (Dis)ability Film. Dr. Luciana co-wrote and co-produced this pilot with Del Weston, ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 4Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 5Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 6Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 7Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 8Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2Health News:Actor/Writer/Director/Psychology Professor Luciana Lagana Receives Three Wins at the 2015 Global Independent Film Awards for the TV Pilot Dr. Luciana on Aging and Falling 2
... , TUESDAY, Sept. 27 (HealthDay News) -- Rude employee ... from many businesses, a new U.S. study finds. ... said they,d experienced or witnessed insensitive, disrespectful or rude ... consumers said this incivility makes them less likely to ...
... rates linked to climate change will increase in several European ... study, which will be presented today (27 September 2011) at ... Belgium, France, Spain and Portugal will see the biggest climate-induced ... The research is part of the Climate-TRAP project and ...
... birth can have on the lungs of babies could be ... prematurely but may be reversed in their teenage years, according ... at the European Respiratory Society Annual Congress in Amsterdam today ... allows enough time for the infant to fully grow and ...
... Reporter , MONDAY, Sept. 26 (HealthDay News) -- U.S. health ... of blood clots in women taking newer forms of birth ... short of a definitive statement, the U.S. Food and Drug ... higher risk of blood clots in women taking the "fourth ...
... an ongoing debate: Should men over a certain age be ... treatments that may result in significant side effects if they ... by researchers at UCLA,s Jonsson Comprehensive Cancer Center has shown ... while patients with a single comorbid condition such as peripheral ...
... News) -- People with heart disease who undergo cardiac rehabilitation ... rate after exercise, a new study suggests. Researchers at ... recovery live longer than those whose hearts remain revved up ... that can do that," study author Dr. Leslie Cho, director ...
Cached Medicine News:Health News:Climate change set to increase ozone-related deaths over next 60 years 2Health News:Lung function of moderately premature babies is reduced at 8-9 years but may improve with age 2Health News:Newer Contraceptive Pills Could Raise Clot Risk, FDA Warns 2Health News:Elderly patients may be undertreated for prostate cancer 2Health News:Elderly patients may be undertreated for prostate cancer 3Health News:Cardiac Rehab May Help Heart Patients Live Longer 2
(Date:8/30/2015)... LONDRES, August 30, 2015 ... de l cuidado al paciente ... trayecto   Royal Philips  (NYSE: ... de IntelliSpace Cardiovascular , un sistema web de ... para acceder, analizar y compartir imágenes cardiovasculares e información ...
(Date:8/28/2015)... 2015  Delays in the launch and execution ... the decision-making process, resulting in missed opportunities and ... biopharmaceutical companies to develop a tactical approach to ... and more meaningful insights. According ... three-quarters of benchmarked study participants use review cycle ...
(Date:8/28/2015)... -- Research and Markets ( ... "Investigation Report on China,s Pranoprofen Market, 2010-2019" ... discovered by Welfide (Mitsubishi Tanabe Pharma Corporation formerly ... inflammatory drug, pranoprofen was later developed into eye ... trade name of pranopulin for the treatment of ...
Breaking Medicine Technology:Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2
... NEWTON, Mass., Nov. 3, 2010 Karyopharm Therapeutics Inc., a leader ... $20M Series A financing. The nuclear transport machinery plays an integral ... spectrum of human and animal disease. Karyopharm is focused on the ... i nhibitors of n uclear ...
... that a new market research report is available in its ... http://www.reportlinker.com/p0324749/Quality-for-Biologics.html Quality for Biologics – ... change control, product variation, characterisation, and regulatory concerns ... than sales of small molecule drugs, which grew by not ...
Cached Medicine Technology:Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders 2Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders 3Reportlinker Adds Quality for Biologics 2Reportlinker Adds Quality for Biologics 3Reportlinker Adds Quality for Biologics 4Reportlinker Adds Quality for Biologics 5Reportlinker Adds Quality for Biologics 6
... first time, the Integrated Cytometry Solution ... post-analytical solution coupled with complete LIS ... steps a sample undergoes - and ... one - it delivers a progressive ...
Convective Air Warming Blankets...
MAMMOMAT 3000 Nova supports high-volume screening as well as interventional diagnostics. Versatile procedural capabilities include magnification, stereotactic biopsy, needle localization, and specime...
Inquire...
Medicine Products: